Iguana Healthcare Management LLC trimmed its stake in shares of AveXis, Inc. (NASDAQ:AVXS) by 41.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,500 shares of the company’s stock after selling 12,500 shares during the period. Iguana Healthcare Management LLC owned 0.05% of AveXis worth $1,693,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of AVXS. Strs Ohio purchased a new position in AveXis during the third quarter valued at $116,000. Botty Investors LLC purchased a new position in AveXis during the second quarter valued at $123,000. Ameritas Investment Partners Inc. lifted its holdings in AveXis by 331.0% during the second quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock valued at $174,000 after purchasing an additional 1,622 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in shares of AveXis by 688.6% in the third quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after buying an additional 1,577 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new position in shares of AveXis in the third quarter worth about $200,000. 92.88% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Brian K. Kaspar sold 15,000 shares of the firm’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $101.46, for a total transaction of $1,521,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $97.25, for a total transaction of $173,105.00. Following the sale, the vice president now owns 1,780 shares of the company’s stock, valued at $173,105. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 52,340 shares of company stock valued at $5,172,298. 18.60% of the stock is owned by company insiders.

Several equities analysts have recently weighed in on the stock. BidaskClub downgraded shares of AveXis from a “hold” rating to a “sell” rating in a research note on Thursday. Evercore ISI assumed coverage on shares of AveXis in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $120.00 price target on the stock. Royal Bank of Canada reissued a “hold” rating and issued a $92.00 price target on shares of AveXis in a research note on Thursday, November 2nd. Wells Fargo & Company reissued an “outperform” rating and issued a $134.00 price target (up from $89.00) on shares of AveXis in a research note on Tuesday, September 5th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $123.00 price target on shares of AveXis in a research note on Saturday, September 30th. Four investment analysts have rated the stock with a sell rating, three have given a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $110.67.

Shares of AveXis, Inc. (NASDAQ:AVXS) opened at $98.34 on Thursday. AveXis, Inc. has a 12-month low of $44.68 and a 12-month high of $108.27.

AveXis (NASDAQ:AVXS) last released its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same period in the previous year, the business posted ($0.87) EPS. equities analysts predict that AveXis, Inc. will post -6.23 earnings per share for the current year.

WARNING: “AveXis, Inc. (AVXS) Holdings Cut by Iguana Healthcare Management LLC” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/14/avexis-inc-avxs-holdings-cut-by-iguana-healthcare-management-llc.html.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Institutional Ownership by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Stock Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related stocks with our FREE daily email newsletter.